|
| Report (number of cases and grades) | Antibody used | Immunostaining percentage | Correlations with clinicopathological features | Other correlations | Survival analysis |
|
| Korkolopoulou et al. [30] (111 patients: 25 grade II, 15 III, and 71 IV) | Rabbit monoclonal anti-p-mTOR (Ser2448) ab (CST), diluted 1 : 50 for IHC and 1 : 1.000 (WB) | (i) 84.7% (94/111) cytoplasmic/membranous
(ii) 2.7% (3/111) nuclear | Gade III and IV marginally higher p-mTOR expression than grade II | p-mTOR with
(i) nuclear and cytoplasmic p-AKT
(ii) p-p70S6K
(iii) p-4E-BP1
(iv) VEGF | p-mTOR with worse DFS |
| Li et al. [14] (87 patients: 27 grade I-II, 24 III, and 36 IV) | Rabbit monoclonal anti-p-mTOR (Ser2448) ab (EP), diluted 1 : 100 (IHC) | (i) 74.7% (65/87) nuclear and/or cytoplasmic
(ii) 44.4% of grade IV strong expression | p-mTOR with tumor grade | — | — |
| Annovazzi et al. [18] (54 patients: 10 grade II, 10 III, and 34 IV) | Rabbit polyclonal anti-p-mTOR (Ser2448) ab (CST), diluted 1 : 75 (IHC) | 0%, 70%, and 81.8% nuclear in grade II, III, and IV, respectively | p-mTOR with tumor grade | p-mTOR with
(i) p-AKT
(ii) inversely Beclin 1 | No significant correlation |
| Pelloski et al. [22] (268 grade IV) | Anti-p-mTOR (Ser2448) ab (CST), diluted 1 : 100 (IHC) | Not provided | — | p-mTOR with
(i) p-ERK
(ii) p-p70S6K
(iii) p-AKT
(iv) PTEN
(v) YKL-40 | (i) p-mTOR with shorter OS
(ii) Multivariate analysis: not retained as an independent prognostic factor |
| Riemenschneider et al. [23] (29 grade IV) | Rabbit polyclonal anti-p-mTOR (Ser2448) ab (CST), diluted 1 : 75 (IHC) | Not provided | — | No significant correlation | — |
| Choe et al. [26] (45 grade IV) | p-mTOR (Ser2481) ab (CST), diluted 1 : 50 (IHC) | Not provided | — | p-mTOR with
(i) p-AKT
(ii) p-S6
(iii) EGFRvIII | — |
|
